$10.05
+0.14 (+1.41%)
Open$10.01
Previous Close$9.91
Day High$10.25
Day Low$9.88
52W High$10.75
52W Low$4.52
Volume—
Avg Volume25.0K
Market Cap88.75M
P/E Ratio—
EPS$-0.06
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-57.5% upside
Current
$10.05
$10.05
Target
$4.27
$4.27
$3.74
$4.27 avg
$6.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 27.76M | 24.32M | 25.83M |
| Net Income | -1,044,320 | -823,163 | 1.23M |
| Profit Margin | -3.8% | -3.6% | 4.8% |
| EBITDA | 2.13M | 1.77M | 1.46M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +14.2% | +14.2% | +0.8% |
| Debt/Equity | 0.34 | 0.34 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |